Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn’s disease in China

doi:10.3748/wjg.v32.i8.115291

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 8

This Article

(45)

(47)

(1)

(0)

(1)

(1066)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Feb 28, 2026; 32(8): 115291
Published online Feb 28, 2026. doi: 10.3748/wjg.v32.i8.115291

Table 3 Summary of net monetary benefit and incremental cost-effectiveness ratio results in base case analysis comparing different biologic sequences for biologic-naïve Crohn’s disease patients

Sequence	Costs ($)	QALY	Net monetary benefit ($)	Incremental costs ($)	Incremental QALYs	Incremental cost-effectiveness ratio ($/QALY)¹
Sequence 1: VDZ-UST	22392.37	3.967	30948.45	-	-	-
Sequence 2: IFX-ADA	23555.90	4.117	31790.65	1163.52	0.149	7799.27
Sequence 3: ADA-UST	23396.38	4.407	35850.93	1004.01	0.439	2285.38
Sequence 4: IFX-UST	24697.41	4.272	32741.92	2305.04	0.305	7561.41
Sequence 5: ADA-VDZ	23127.51	4.248	33981.33	735.13	0.280	2623.04
Sequence 6: UST-VDZ	24271.51	4.335	34005.35	1879.14	0.367	5118.36
Sequence 7: IFX-VDZ	24446.82	4.101	30686.86	2054.45	0.133	15406.35
Sequence 8: IFX-UST-VDZ	27191.67	4.322	30920.52	4799.30	0.355	13523.37
Sequence 9: IFX-ADA-VDZ	26236.50	4.171	29844.52	3844.12	0.204	18861.04
Sequence 10: IFX-UST-ADA	26366.71	4.337	31936.78	3974.34	0.369	10767.13
Sequence 11: IFX-ADA-UST	26397.00	4.333	31856.02	4004.63	0.365	10960.66
Sequence 12: IFX-VDZ-UST	27305.37	4.318	30751.11	4913.00	0.351	14007.32
Sequence 13: ADA-UST-VDZ	25665.78	4.453	34207.27	3273.41	0.486	6737.35
Sequence 14: ADA-VDZ-UST	25762.83	4.450	34062.39	3370.46	0.482	6988.27
Sequence 15: UST-VDZ-ADA	25821.32	4.396	33277.94	3428.95	0.428	8005.84
Sequence 16: VDZ-ADA-UST	24281.88	4.037	29989.99	1889.51	0.069	27285.02
Sequence 17: VDZ-UST-ADA	24256.07	4.040	30061.27	1863.70	0.073	25659.35

¹Compared to sequence 1 (vedolizumab-ustekinumab).

ADA: Adalimumab; IFX: Infliximab; QALYs: Quality-adjusted life years; UST: Ustekinumab; VDZ: Vedolizumab.

Full Size Table

Citation: Wu Y, Tao LB, Liu C, Wang FX, Yan Y, Sun S. Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn’s disease in China. World J Gastroenterol 2026; 32(8): 115291
URL: https://www.wjgnet.com/1007-9327/full/v32/i8/115291.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i8.115291

Wu Y, Tao LB, Liu C, Wang FX, Yan Y, Sun S. Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn’s disease in China. World J Gastroenterol 2026; 32(8): 115291 [PMID: 41809880 DOI: 10.3748/wjg.v32.i8.115291]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.